E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Undifferentiated Arthritis |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the proportion of subjects with CCP-negative, power Doppler positive Undifferentiated Arthritis who on open-label Abatacept medication achieve the following criteria at 6 months: 1. DAS44 remission i.e. DAS44-CRP < 1.6 2. Maximum of one swollen joint for at least 3 consecutive months 3. No radiographic progression defined as change that does not exceed the smallest detectable change over one year
|
|
E.2.2 | Secondary objectives of the trial |
1) Assess proportion of subjects: Achieve DAS44 remission Achieve DAS28 remission Achieve modified ACR remission (mACRR) With persistent symptomatic clinical synovitis
2) Assess disease activity over time
3) Assess degree of synovitis using power Doppler US imaging; assess structural joint damage with plain radiography of the hands using Genant-modified Sharp Score; and bone densitometry.
4) Assess physical function and health-related quality of life using SF-36 and Disability Index of HAQ, respectively as well as EQ-5D health outcome and quality of life assessment using RAQoL
5) Determine steroid need for duration of the study
6) Record proportion of patients that progress to RA (or any other autoimmune disease) |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
ASUS: Biological Sub-Study Exploratory Objective = To evaluate change in immunological parameters at weeks -4, 12, 24, 36 and 48 (as part of a biological sub-study)
|
|
E.3 | Principal inclusion criteria |
Subjects must have a diagnosis of UA defined as: - A subject with symptomatic clinical synovitis of two or more joints. - Subjects must not meet diagnostic criteria for any other rheumatic disease (e.g., lupus erythematous). - The subject’s disease duration [defined as the time from the onset of symptoms (joint pain, swelling, or stiffness) of arthritis to enrollment must be > 12 weeks and < one year. - Power Doppler positive signal of >/= 1 (10 patients with PD = 1; 10 patients with PD >/= 2) - Subjects must be negative for autoantibodies against cyclic citrullinated peptides by ELISA and rheumatoid factor. - No prior therapy with DMARD or biologic therapy.
Age and Gender - Men and women, ages 18 - 75 years old. - Men and Women of childbearing potential are eligible if they are practicing effective contraceptive measures. - Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 10 weeks after the last infusion of Abatacept in such a manner that the risk of pregnancy is minimised. - WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal [defined as amenorrhea ≥ 12 consecutive months; or women on hormone replacement therapy (HRT) with documented serum follicle stimulating hormone (FSH) level > 35mIU/mL]. - Women who are using oral, implanted or injectable contraceptive hormones or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy or practicing abstinence or where partner is sterile (e.g., vasectomy), should be considered to be of child bearing potential. - WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 48 hours prior to the start of study medication - Male subjects must be using an adequate method of contraception throughout the study including up to 10 weeks after the last infusion of Abatacept so that the risk of pregnancy to their partner is minimised. |
|
E.4 | Principal exclusion criteria |
Women and Reproductive Status - WOCBP who are unwilling or unable to adhere to an acceptable form of contraception throughout the period of the study timetable and for up to 10 weeks after the last infusion of Abatacept - Women who are pregnant or breastfeeding - Women with a positive pregnancy test on enrollment or prior to study drug administration - Males unwilling or unable to use an adequate method of contraception for the entire study period and for up to 10 weeks after the last infusion of study medication.
Medical History and Concurrent Diseases - Subjects who are impaired, incapacitated, or incapable of completing study related assessments. - Subjects who meet diagnostic criteria for any other rheumatic disease (e.g., lupus erythematous). - UA duration of greater than one year - Subjects who have previously received treatment with a DMARD or an approved biologic RA therapy (infliximab, etanercept, anakinra, adalimumab). - Subjects who have received ≥ 1 steroid injection (IM/IA) within 6 week period prior to baseline - Subjects with active vasculitis of a major organ system. - Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, cardiac, neurological, or cerebral disease. - Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study. - Subjects with a history of cancer within the last five years (other than non-melanoma skin cell cancers cured by local resection). Existing non-melanoma skin cell cancers must be removed prior to dosing. - Subjects with any serious acute bacterial infection (such as pneumonia or pyelonephritis unless treated and completely resolved with antibiotics). - Subjects with severe chronic or recurrent bacterial infections (such as recurrent pneumonia, chronic bronchiectasis). - Subjects with active tuberculosis (TB) requiring treatment within the previous years. - Subjects with a positive mantoux test at screening will not be eligible for the study unless active TB infection has been ruled out. A mantoux test response that is equal to or greater than 10 mm should be considered a positive test, although a lower threshold (5 mm) may be applied as determined by the clinical circumstance and investigator according to published guidelines and/or local standards endorsed by the medical society.
Physical and Laboratory Test Findings - Hepatitis B surface antigen-positive subjects. - Hepatitis C antibody-positive subjects who are also RIBA-positive or PCR-positive. - Subjects with any of the following laboratory values: o Haemoglobin < 8.5 g/dL. o WBC < 3,000/mm3 (3 x 109/L) o Platelets < 100,000/mm3 (100 x 109/L). o Serum creatinine > 2 times upper limit of normal. o Serum ALT or AST > 2 times upper limit of normal. o Any other laboratory test results that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study.
Prohibited Therapies and/or Medications - Prior treatment with any DMARD or biological therapy before screening.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoints of this study will therefore be the following at 6 months: 1. DAS44 remission i.e. DAS44-CRP < 1.6 2. Maximum of one swollen joint for at least 3 consecutive months 3. No radiographic progression defined as change that does not exceed the smallest detectable change over one year
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |